225 related articles for article (PubMed ID: 32162057)
21. Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.
Beck TN; Kaczmar J; Handorf E; Nikonova A; Dubyk C; Peri S; Lango M; Ridge JA; Serebriiskii IG; Burtness B; Golemis EA; Mehra R
Oncotarget; 2015 Aug; 6(22):18863-74. PubMed ID: 26265441
[TBL] [Abstract][Full Text] [Related]
22. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
23. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.
Akervall J; Bockmühl U; Petersen I; Yang K; Carey TE; Kurnit DM
Clin Cancer Res; 2003 May; 9(5):1750-5. PubMed ID: 12738730
[TBL] [Abstract][Full Text] [Related]
24. [Expression of CDK4 and p16 in laryngeal squamous cell carcinoma].
Zhang J; Geng M; Su L; Zhang H; Lu X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):108-10. PubMed ID: 25989653
[TBL] [Abstract][Full Text] [Related]
25. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
[TBL] [Abstract][Full Text] [Related]
26. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
[TBL] [Abstract][Full Text] [Related]
27. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
28. Coordinated expression of cyclin-dependent kinase-4 and its regulators in human oral tumors.
Poi MJ; Knobloch TJ; Sears MT; Uhrig LK; Warner BM; Weghorst CM; Li J
Anticancer Res; 2014 Jul; 34(7):3285-92. PubMed ID: 24982332
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas.
Chen Y; Li Z; Fang Q; Wang H; Li C; Gao H; Zhang Y
Int J Mol Med; 2021 Feb; 47(2):500-510. PubMed ID: 33416096
[TBL] [Abstract][Full Text] [Related]
30. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
31. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
32. p16, HPV, and Cetuximab: What Is the Evidence?
Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
[TBL] [Abstract][Full Text] [Related]
33. [The expression of Rb, p16 and cyclin D1 in 41 esophageal cancers].
Zheng J; Zhou C; Xiao F
Zhonghua Bing Li Xue Za Zhi; 1996 Dec; 25(6):336-9. PubMed ID: 9388858
[TBL] [Abstract][Full Text] [Related]
34. [Relationship between human papilloma virus infection and expression of p16 and EGFR in head and neck squamous cell carcinoma and their prognostic significance].
Ma L; Wang D; Wufuer A; Wu R; Zhang S; Wang R
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):23-8. PubMed ID: 24685082
[TBL] [Abstract][Full Text] [Related]
35. Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
Ghazizadeh M; Jin E; Shimizu H; Fujiwara M; Arai S; Ohaki Y; Takemura T; Kawanami O
Respiration; 2005; 72(1):68-73. PubMed ID: 15753637
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
[TBL] [Abstract][Full Text] [Related]
37. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
38. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
39. Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
Zhu L; Luo Q; Bi J; Ding J; Ge S; Chen F
Chem Biol Interact; 2014 Dec; 224():149-56. PubMed ID: 25450235
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathways: CDK4 inhibitors for cancer therapy.
Dickson MA
Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
